查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679434

胜肽药物偶联物市场规模、份额、趋势分析报告：按产品类型、地区和细分市场预测，2025-2030 年

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

胜肽药物偶联物市场的成长和趋势

根据Grand View Research, Inc.的最新报告，到2030年全球胜肽药物偶联物市场规模预计将达到128.4亿美元，预计2025年至2030年期间的复合年增长率为19.21%。

市场成长的动力包括全球癌症患者数量和相关死亡率的快速成长、胜肽药物偶联物 (PDC) 强大的临床测试管道以及现有产品的相关副作用，例如与小分子化疗药物相关的不可控的毒性。

据世界卫生组织称，癌症是全球疾病相关死亡的主要原因。 2020年，全球约有1,000万人、美国超过600万人死于癌症。此外，根据 cancer.gov 的数据，到 2040 年，每年新增癌症病例和癌症相关死亡人数预计将达到 2,900 万，每年新增癌症病例和癌症相关死亡人数预计将达到 1,600 万人。因此，针对不受控制的细胞增殖的 PDC 等新型疗法的需求不断增长，预计将推动胜肽药物偶联物市场的成长。

目前，Lutathera（Lu 177 dotatate）和Pepaxto（Melflufen）是FDA核准用于治疗不受控制的细胞增殖的两种PDC。市面上有一种经 FDA核准的PDC，即诺华的 Lutathera（镏Lu 177），用于治疗成人生长抑制素受体阳性的胃肠胰神经内分泌肿瘤。随后，2021 年 2 月，Oncopeptides ABs 宣布 FDA 加速核准Pepaxto（Melphalan）用于治疗多发性骨髓瘤。由于 PDC 在该领域的存在有限，因此存在着有利可图的成长机会。

此外，强大的临床测试管道和新型 PDC 的推出预计将在预测期内推动市场成长。其中包括处于脑癌 3 期临床试验的 PDC ANG1005，以及处于肺癌 2 期临床试验的 PDC BT5528 和 BT1718。 CBX-12 也是用于治疗小细胞肺癌的第 2 期 PDC 候选药物。

主要企业正在采取合作研究、併购、协议等策略性倡议以及金融投资，这些措施正在推动市场成长。例如，2021 年 12 月，Coherent Biopharma 与药明康德合全宣布达成策略伙伴关係协议，以开发涉及胜肽-药物偶联物的当前和未来疗法。

胜肽药物偶联物市场报告重点

  • 预计治疗领域将主导该行业并在 2024 年实现最快的成长。
  • 预计到 2024 年，Pulvic 部门将以 42.52% 的收益占有率占据行业主导地位，并在预测期内呈现最快的复合年增长率。
  • 2024年北美胜肽药物偶联物市场占据主导，占全球份额的75.02%。

目录

第一章调查方法与范围

第二章执行摘要

3. 胜肽药物偶联物市场变数、趋势和范围

  • 母市场展望
  • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多巴胺促效剂分析工具
    • 波特的分析
    • PESTEL分析
  • 管道分析
    • 第一阶段
    • 第 2 阶段
    • 第 3 阶段

第四章胜肽药物偶联物市场：按产品分類的估计和趋势分析

  • 胜肽药物偶联物市场：产品细分仪表板
  • 胜肽药物偶联物市场：2024 年与 2030 年产品差异分析
  • 伊卢奇克斯
  • 普尔维克特
  • 卢塔瑟拉
  • 奥曲肽
  • 其他的

第五章胜肽药物偶联物市场：按类型估计和趋势分析

  • 胜肽药物偶联物市场：类型细分仪表板
  • 胜肽药物偶联物市场：类型变异分析（2024 年 vs 2030 年）
  • 治疗
  • 诊断

第六章胜肽药物偶联物市场：区域、估计和趋势分析

  • 2024 年及 2030 年胜肽药物偶联物市场占有率（百万美元）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 参与者概述
  • 产品基准
  • 2024年公司市场占有率分析
  • 公司简介
    • Novartis AG
    • AstraZeneca
    • Oncopeptides AB
    • Bicycle Therapeutics
    • Cybrexa
    • Angiochem Inc.
    • Soricimed Biopharma
    • Theratechnologies Inc.

第 8 章 结论

Product Code: GVR-4-68040-001-8

Peptide Drug Conjugates Market Growth & Trends:

The global peptide drug conjugates market size is estimated to reach USD 12.84 billion by 2030, registering to grow at a CAGR of 19.21% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis's Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA's accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights:

  • The therapeutic segment dominated the industry in 2024 and is anticipated to witness the fastest growth.
  • The pluvicto segment dominated the industry with a revenue share of 42.52% in 2024 and is expected to exhibit the fastest CAGR over the forecast period.
  • North America peptide drug conjugates market held a leading position in 2024, accounting for 75.02% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market drivers analysis
      • 3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
      • 3.3.1.2. Robust clinical trial pipeline
      • 3.3.1.3. Growing focus on targeted drug delivery
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Long R&D time and slow clinical development process
      • 3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC's)
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis

  • 4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
  • 4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Illuccix
    • 4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Pluvicto
    • 4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lutathera
    • 4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. OctreoScan
    • 4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis

  • 5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
  • 5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Therapeutics
    • 5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Diagnostics
    • 5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis

  • 6.1. Peptide Drug Conjugates Market Share, By Region, 2024 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target Disease Prevalence
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Reimbursement Framework
      • 6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Reimbursement Framework
      • 6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Reimbursement Framework
      • 6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Framework
      • 6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Framework
      • 6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Reimbursement Framework
      • 6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Reimbursement Framework
      • 6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Reimbursement Framework
      • 6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Reimbursement Framework
      • 6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Reimbursement Framework
      • 6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Reimbursement Framework
      • 6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Framework
      • 6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Framework
      • 6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Framework
      • 6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Participant Overview
  • 7.4. Financial Performance
  • 7.5. Product Bench Marking
  • 7.6. Company Market Share Analysis, 2024
  • 7.7. Company Profiles
    • 7.7.1. Novartis AG
      • 7.7.1.1. Participant's Overview
      • 7.7.1.2. Financial Performance
      • 7.7.1.3. Product Benchmarking
      • 7.7.1.4. Recent Developments/ Strategic Initiatives
    • 7.7.2. AstraZeneca
      • 7.7.2.1. Participant's Overview
      • 7.7.2.2. Financial Performance
      • 7.7.2.3. Product Benchmarking
      • 7.7.2.4. Recent Developments/ Strategic Initiatives
    • 7.7.3. Oncopeptides AB
      • 7.7.3.1. Participant's Overview
      • 7.7.3.2. Financial Performance
      • 7.7.3.3. Product Benchmarking
      • 7.7.3.4. Recent Developments/ Strategic Initiatives
    • 7.7.4. Bicycle Therapeutics
      • 7.7.4.1. Participant's Overview
      • 7.7.4.2. Financial Performance
      • 7.7.4.3. Product Benchmarking
      • 7.7.4.4. Recent Developments/ Strategic Initiatives
    • 7.7.5. Cybrexa
      • 7.7.5.1. Participant's Overview
      • 7.7.5.2. Financial Performance
      • 7.7.5.3. Product Benchmarking
      • 7.7.5.4. Recent Developments/ Strategic Initiatives
    • 7.7.6. Angiochem Inc.
      • 7.7.6.1. Participant's Overview
      • 7.7.6.2. Financial Performance
      • 7.7.6.3. Product Benchmarking
      • 7.7.6.4. Recent Developments/ Strategic Initiatives
    • 7.7.7. Soricimed Biopharma
      • 7.7.7.1. Participant's Overview
      • 7.7.7.2. Financial Performance
      • 7.7.7.3. Product Benchmarking
      • 7.7.7.4. Recent Developments/ Strategic Initiatives
    • 7.7.8. Theratechnologies Inc.
      • 7.7.8.1. Participant's Overview
      • 7.7.8.2. Financial Performance
      • 7.7.8.3. Product Benchmarking
      • 7.7.8.4. Recent Developments/ Strategic Initiatives

Chapter 8. Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 List of Parameters
  • Table 4 List of Distributors
  • Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
  • Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 15 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 21 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 25 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Denmark Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 31 Denmark Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 Sweden Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Sweden Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Norway Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Norway Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 40 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 42 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 44 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 45 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 46 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 47 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 48 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 49 Thailand Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 50 Thailand Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 52 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 53 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 55 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 68 Kuwait Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide drug conjugates market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and type segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Peptide therapeutics market value, 2024 (USD billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Peptide Drug Conjugates market: Product outlook and key takeaways
  • Fig. 17 Peptide drug conjugates market: Product movement analysis
  • Fig. 18 Lutathera market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 OctreoScan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Illuccix market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Pluvicto market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Peptide drug conjugates market: Type outlook and key takeaways
  • Fig. 24 Peptide drug conjugates market: Type movement analysis
  • Fig. 25 Therapeutic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diagnostic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Peptide drug conjugates market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 U.S. peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Canada peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 Mexico peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 UK peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Germany peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 France peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Italy peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Spain peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Denmark peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Sweden peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Norway peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Japan peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 China peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 India peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Australia peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Thailand peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 South Korea peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Brazil peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Argentina peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 South Africa peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 UAE peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Kuwait peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Company/competition categorization
  • Fig. 85 Company market share analysis, 2024
  • Fig. 86 Strategy mapping